Hong-Wu Shen - The Consciousness Library

Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice

Acta Pharmaceutica Sinica B August 6, 2016 Xi-Ling Jiang, Hong-Wu Shen, Donald E. Mager et al. 4 citations

We have shown recently that concurrent harmaline, a monoamine oxidase-A inhibitor (MAOI), potentiates serotonin (5-HT) receptor agonist 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)-induced hyperthermia. The objective of this study was to develop an integrated pharmacokinetic/pharmacodynamic (PK/PD) model to characterize and predict the thermoregulatory effects of such serotonergic drugs in...

DOI: 10.1016/j.apsb.2016.07.007 Serotonergic Serotonin Harmaline Hyperthermia +5

Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Pharmacological reports : PR June 1, 2016 Xi-Ling Jiang, Hong-Wu Shen, Ai-Ming Yu 13 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and harmaline are indolealkylamine (IAA) drugs often abused together. Our recent studies have revealed the significant effects of co-administered harmaline, a monoamine oxidase inhibitor (MAOI), on 5-MeO-DMT pharmacokinetics and thermoregulation. This study was to delineate the impact of harmaline and 5-MeO-DMT on home-cage activity in mouse models,...

DOI: 10.1016/j.pharep.2016.01.008 Full text 5-HT Receptor Harmaline Maoi 5-MEO-DMT Combination +14

Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Neuropharmacology February 1, 2015 Xi-Ling Jiang, Hong-Wu Shen, Ai-Ming Yu 26 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and harmaline are serotonin (5-HT) analogs often abused together, which alters thermoregulation that may indicate the severity of serotonin toxicity. Our recent studies have revealed that co-administration of monoamine oxidase inhibitor harmaline leads to greater and prolonged exposure to 5-HT agonist 5-MeO-DMT that might be influenced by cytochrome...

DOI: 10.1016/j.neuropharm.2014.10.013 Full text Thermoregulation Temperature control Thermal regulation Drug interaction +13

Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.

Drug metabolism and disposition: the biological fate of chemicals May 1, 2013 Xi-Ling Jiang, Hong-Wu Shen, Donald E. Mager et al. 29 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating...

DOI: 10.1124/dmd.112.050724 Full text Pharmacokinetics Drug interactions Drug metabolism Designer drugs

Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.

Drug metabolism and disposition: the biological fate of chemicals July 1, 2011 Hong-Wu Shen, Xi-Ling Jiang, Ai-Ming Yu 29 citations

5-Methoxy-N,N,-dimethyltryptamine (5-MeO-DMT), an abused serotonergic indolealkylamine drug, was placed into Schedule I controlled substance status in the United States as of January 19, 2011. In previous studies, we have shown the impact of monoamine oxidase A and cytochrome P450 2D6 enzymes on 5-MeO-DMT metabolism and pharmacokinetics. The aim of this study was to investigate 5-MeO-DMT...

DOI: 10.1124/dmd.111.039107 Full text 5-MEO-DMT Nonlinear pharmacokinetics Drug metabolism Animal research

Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.

Current Drug Metabolism October 1, 2010 Hong-Wu Shen, Xi-Ling Jiang, Jerrold C Winter et al. 171 citations

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) belongs to a group of naturally-occurring psychoactive indolealkylamine drugs. It acts as a nonselective serotonin (5-HT) agonist and causes many physiological and behavioral changes. 5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination...

DOI: 10.2174/138920010794233495 Full text Psychedelic Metabolism: 5-MEO-DMT Bufotenine Transform Metabolized +11

Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.

Biochemical Pharmacology July 1, 2010 Hong-Wu Shen, Chao Wu, Xi-Ling Jiang et al. 40 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a natural psychoactive indolealkylamine drug that has been used for recreational purpose. Our previous study revealed that polymorphic cytochrome P450 2D6 (CYP2D6) catalyzed 5-MeO-DMT O-demethylation to produce active metabolite bufotenine, while 5-MeO-DMT is mainly inactivated through deamination pathway mediated by monoamine oxidase (MAO). This...

DOI: 10.1016/j.bcp.2010.02.020 Full text Drug metabolism Biotransformation Pharmacokinetics Drug processing +13

Development of a LC–MS/MS Method to Analyze 5-Methoxy-N,N-Dimethyltryptamine and Bufotenine: Application to Pharmacokinetic Study

Bioanalysis March 27, 2009 Hong-Wu Shen, Xi-Ling Jiang, Ai-Ming Yu 26 citations

INTRODUCTION: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychoactive indolealkylamine substance that has been used for recreational purpose and may lead to fatal toxicity. While 5-MeO-DMT is mainly inactivated via deamination, it is O-demethylated to an active metabolite, bufotenine. Quantitation of 5-MeO-DMT and bufotenine is essential to understand the exposure to and the effects of...

DOI: 10.4155/bio.09.7 Chromatography Metabolite Protein precipitation Pharmacokinetics +1

Papers